If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

por Köhler, Jens, Jänne, Pasi A.
Publicado 2021

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC

por Strickland, Matthew R., Jänne, Pasi A.
Publicado 2020

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

por Cortot, Alexis B., Jänne, Pasi A.
Publicado 2014

Kinase drug discovery 20 years after imatinib: progress and future directions

por Cohen, Philip, Cross, Darren, Jänne, Pasi A.
Publicado 2021

s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis

por Li, Jin, Berbeco, Ross, Distel, Robert J., Jänne, Pasi A., Wang, Lilin, Makrigiorgos, G. Mike
Publicado 2007

Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells

por Wang, Jun, Mikse, Oliver, Liao, Rachel G., Li, Yvonne, Tan, Li, Janne, Pasi A., Gray, Nathanael S., Wong, Kwok-kin, Hammerman, Peter S.
Publicado 2014

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

por Nishino, Mizuki, Ramaiya, Nikhil H., Chambers, Emily S., Adeni, Anika E., Hatabu, Hiroto, Jänne, Pasi A., Hodi, F. Stephen, Awad, Mark M.
Publicado 2016

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

por Wang, Haiyun, Lv, Qi, Xu, Yue, Cai, Zhaoqing, Zheng, Jie, Cheng, Xiaojie, Dai, Yao, Jänne, Pasi A., Ambrogio, Chiara, Köhler, Jens
Publicado 2019

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

por Deng, Xianming, Wang, Jinhua, Zhang, Jianming, Sim, Taebo, Kim, Nam Doo, Sasaki, Takaaki, Luther, William, George, Rani E., Jänne, Pasi A., Gray, Nathanael S.
Publicado 2011

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

por Ou, Sai-Hong Ignatius, Fujiwara, Yutaka, Shaw, Alice T., Yamamoto, Noboru, Nakagawa, Kazuhiko, Fan, Frank, Hao, Yuki, Gao, Yanfei, Jänne, Pasi A., Seto, Takashi
Publicado 2020

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

por Wakelee, Heather A., Gettinger, Scott, Engelman, Jeffrey, Jänne, Pasi A., West, Howard, Subramaniam, Deepa S., Leach, Joseph, Wax, Michael, Yaron, Yifah, Miles, Dale R., Lara, Primo N.
Publicado 2017

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

por Keegan, Alissa, Ricciuti, Biagio, Garden, Padric, Cohen, Limor, Nishihara, Reiko, Adeni, Anika, Paweletz, Cloud, Supplee, Julianna, Jänne, Pasi A, Severgnini, Mariano, Awad, Mark M, Walt, David R
Publicado 2020

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

por Pujol, Jean-Louis, Vansteenkiste, Johan, Paz-Ares Rodríguez, Luis, Gregorc, Vanesa, Mazieres, Julien, Awad, Mark, Jänne, Pasi A., Chisamore, Michael, Hossain, Anwar M., Chen, Yanyun, Beck, J. Thaddeus
Publicado 2021

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

por Greulich, Heidi, Chen, Tzu-Hsiu, Feng, Whei, Jänne, Pasi A, Alvarez, James V, Zappaterra, Mauro, Bulmer, Sara E, Frank, David A, Hahn, William C, Sellers, William R, Meyerson, Matthew
Publicado 2005

The fuzzy world of precision medicine: deliberations of a precision medicine tumor board

por McGraw, Sarah A, Garber, Judy, Jänne, Pasi A, Lindeman, Neal, Oliver, Nelly, Sholl, Lynette M, Van Allen, Eliezer M, Wagle, Nikhil, Garraway, Levi A, Joffe, Steven, Gray, Stacy W
Publicado 2017

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

por Garcia Campelo, Maria Rosario, Zhou, Caicun, Ramalingam, Suresh S., Lin, Huamao M., Kim, Tae Min, Riely, Gregory J., Mekhail, Tarek, Nguyen, Danny, Goodman, Erin, Mehta, Minal, Popat, Sanjay, Jänne, Pasi A.
Publicado 2022

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

por Yuen, Hiu-Fung, Abramczyk, Olga, Montgomery, Grant, Chan, Ka-Kui, Huang, Yu-Han, Sasazuki, Takehiko, Shirasawa, Senji, Gopesh, Srivastava, Chan, Kwok-Wah, Fennell, Dean, Janne, Pasi, El-Tanani, Mohamed, Murray, James T.
Publicado 2012

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer

por Awad, Mark M., Mastini, Cristina, Blasco, Rafael B., Mologni, Luca, Voena, Claudia, Mussolin, Lara, Mach, Stacy L., Adeni, Anika E., Lydon, Christine A., Sholl, Lynette M., Jänne, Pasi A., Chiarle, Roberto
Publicado 2017

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

por Negrao, Marcelo V., Spira, Alexander I., Heist, Rebecca S., Jänne, Pasi A., Pacheco, Jose M., Weiss, Jared, Gadgeel, Shirish M., Velastegui, Karen, Yang, Wenjing, Der-Torossian, Hirak, Christensen, James G., Sabari, Joshua K.
Publicado 2023

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

por Beyett, Tyler S., To, Ciric, Heppner, David E., Rana, Jaimin K., Schmoker, Anna M., Jang, Jaebong, De Clercq, Dries J. H., Gomez, Gabriel, Scott, David A., Gray, Nathanael S., Jänne, Pasi A., Eck, Michael J.
Publicado 2022